期刊文献+

Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage:an experimental study with nu/nu athymic mice 被引量:4

Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage:an experimental study with nu/nu athymic mice
原文传递
导出
摘要 Background and objective:Gonadotropin-releasing hormone (GnRH) plays an important role in the regulation of ovarian function and ovarian cancer cell growth. In this study, we determined whether administration of the GnRH agonist (GnRHa), triporelin, prior to cisplatin treatment affects cisplatin and/or prevents cisplatin-induced ovarian damage. Methods:nu/nu mice were injected with ovarian cancer OVCAR-3 cells intraperitoneally. After two weeks, the mice were treated with saline (control), cisplatin, GnRHa, or cisplatin plus GnRHa for four weeks. At the end of the experimental protocol, blood, tumor, ovary, and uterine tissues were resected for hematoxylin and eosin (H&E) staining, immunohistochemical analyses of Ki67, nuclear factor-κB (NF-κB), and caspase-3, transmission electron microscopy of apoptosis, or enzyme-linked immunosorbent assay (ELISA) analyses of anti-Mullerian hormone (AMH). Results:Cisplatin treatment effectively inhibited tumor growth in mice treated with human ovarian cancer cells; however the treatment also induced considerable toxicity. Immunohistochemical analyses showed that Ki67 expression was reduced in cisplatin-treated mice compared to control (P<0.05), but there was no statistically significant differences between cisplatin-treated mice and cisplatin plus GnRHa-treated mice (P>0.05), while expressions of NF-κB and caspase-3 were reduced and induced, respectively, in cisplatin-treated mice and cisplatin plus GnRHa-treated mice. Apoptosis occurred in the GnRHa, cisplatin, and cisplatin plus GnRHa-treated mice, but not in control mice. Ovaries exposed to GnRHa in both GnRHa mice and cisplatin-treated mice (combination group) had significantly more primordial and growth follicles and serum levels of AMH than those in the control mice and cisplatin-treated mice (P<0.05). Conclusions:Administration of GnRHa to mice significantly decreased the extent of ovarian damage induced by cisplatin, but did not affect the anti-tumor activity of cisplatin. Background and objective: Gonadotropin-releasing hormone (GnRH) plays an important role in the regulation of ovarian function and ovarian cancer cell growth. In this study, we determined whether administration of the GnRH agonist (GnRHa), triporelin, prior to cisplatin treatment affects cisplatin and/or prevents cisptatin-induced ovarian damage. Methods: nu/nu mice were injected with ovarian cancer OVCAR-3 cells intraperitoneally. After two weeks, the mice were treated with saline (control), cisplatin, GnRHa, or cisplatin plus GnRHa for four weeks. At the end of the experimental protocol, blood, tumor, ovary, and uterine tissues were resected for hematoxylin and eosin (H&E) staining, immunohistochemical analyses of Ki67, nuclear factor-κB (NF-κB), and caspase-3, transmission electron microscopy of apoptosis, or enzyme-linked immunosorbent assay (ELISA) analyses of anti-Mullerian hormone (AMH). Results: Cisplatin treatment effectively inhibited tumor growth in mice treated with human ovarian cancer cells; how- ever the treatment also induced considerable toxicity. Immunohistochemical analyses showed that Ki67 expression was reduced in cisplatin-treated mice compared to control (P〈0.05), but there was no statistically significant differ- ences between cisplatin-treated mice and cisplatin plus GnRHa-treated mice (P〉0.05), while expressions of NF-KB and caspase-3 were reduced and induced, respectively, in cisplatin-treated mice and cisplatin plus GnRHa-treated mice. Apoptosis occurred in the GnRHa, cisplatin, and cisplatin plus GnRHa-treated mice, but not in control mice. Ovaries exposed to GnRHa in both GnRHa mice and cisplatin-treated mice (combination group) had significantly more primordial and growth follicles and serum levels of AMH than those in the control mice and cisplatin-treated mice (P〈0.05). Conclusions: Administration of GnRHa to mice significantly decreased the extent of ovarian damage induced by cisplatin, but did not affect the anti-tumor activity of cisplatin.
出处 《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 SCIE CAS CSCD 2012年第11期894-903,共10页 浙江大学学报(英文版)B辑(生物医学与生物技术)
基金 Project (No. 7002691) supported by the Guangdong Provincial Natural Science Foundation of China
关键词 Gonadotrophin-releasing hormone CISPLATIN Ovarian cancer Animal experiment Gonadotrophin-releasing hormone, Cisplatin, Ovarian cancer, Animal experiment
  • 相关文献

参考文献33

  • 1Arencibia,J.M,Schally,A.V. Luteinizing hormonereleasing hormone as an autocrine growth factor in ES-2ovarian cancer cell line[J].International Journal of Oncology,2000,(05):1009-1013.
  • 2Asschert,J.G,Vellenga,E,Ruiters,M.H,de Vries,E.G Asschert,J.G Vellenga,E Ruiters,M.H. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines[J].International Journal of Cancer,1999,(02):244-249.
  • 3Bours,V,Dejardin,E,Goujon-Letawe,F,Merville,M.P,Castronovo,V. The NF-κB transcription factor and cancer:high expression of NF-κB and Iκ B related proteins in tumor cell lines[J].Biochemical Pharmacology,1994,(01):145-149.
  • 4Carter,B.D,Kaltschmidt,C,Kaltschmidt,B,Offenh(a)user,N,B(o)hm-Matthaei,R,Baeuerle,P.A,Barde,Y.A. Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75[J].Science,1996,(5261):542-545.
  • 5Danforth,D.R,Arbogast,L.K,Friedman,C.I. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists[J].Fertility and Sterility,2005,(05):1333-1338.doi:10.1016/j.fertnstert.2004.12.030.
  • 6Emons,G,Schally,A.V. The use of luteinizing hormone-releasing ormone agonists and antagonists in gynecological cancers[J].Human Reproduction,1994,(07):1364-1379.
  • 7Emons,G,Weiss,S,Ortmann,O,Grundker,C,Schulz,K.D. Luteinizing hormone-releasing hormone(LHRH)might act as a negative autocrine regulator of proliferation of human ovarian cancer[J].European Journal of Endocrinology,2000,(06):665-670.
  • 8Emons,G,Ortmann,O,Teichert,H.M,Fassl,H L(o)hrs,U Kullander,S Kauppila,A Ayalon,D Schally,A Oberheuser,F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma.A prospective double blind randomized trial.Decapeptyl Ovarian Cancer Study Group[J].Cancer,1996,(07):1452-1460.
  • 9Enari,M,Sakahira,H,Yokoyama,H,Okawa,K Iwamatsu,A Nagata,S. A caspase-activated DNase that degrades DNA during apoptosis,and its inhibitor ICAD[J].Nature,1998,(6662):43-50.doi:10.1038/34112.
  • 10Grilli,M,Pizzi,M,Memo,M,Spano,P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation[J].Science,1996,(5291):1383-1385.

同被引文献32

  • 1万小云.化疗对卵巢功能的影响[J].国外医学(妇产科学分册),1995,22(5):289-291. 被引量:3
  • 2马晓玲,张学红.促性腺激素释放激素类似物在妇科的应用研究进展[J].生殖医学杂志,2007,16(1):64-67. 被引量:6
  • 3Zhao X J.The experimental study of prevention for premature ovarian failure caused by chemotherapy injury with Gonadotropinreleasing hormone antagonist ( GnRHant ) [D]. Guangzhou: The Fourth Military Medical University, 2011.
  • 4Sun M, Yu J, Ma W Z, et al. To establish a preliminary mouse models of premature ovarian failure combing with alkylating agents [J].Ningxia Med J, 2013,35 ( 9 ) : 780-782.
  • 5YEH J, KIM B, LIANG YJ, etal.Mullerian inhibiting substance as a novel biomarker of cisplatin-induced ovarian damage[J]. Biochem Biophys ResCommun,2006,348 ( 2 ) : 337-344.
  • 6Choi J., Lee B., Lee E., et al.Cryopreservation of ovarian tissues temporarily suppresses the proliferation of granulosa cells in mouse preantral follicles[J].Cryobiology, 2008,56 ( 1 ) :36-42.
  • 7Isabelle Demeestere, Pauline Brice, Fedro A. Peccatori. Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial[J]. Journal Of Randomized Trial, 2013,31 ( 7 ) :903-909.
  • 8Blumenfeld Z, Avivi I, Eckman A, et al.Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure inyoung female patients with Hodgkin lymphoma[ J].Fertil Steril,2008,89 ( 1 ) : 166-173.
  • 9Lemos CN, Reis FM, Pena GN, et al.Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamid[J].Reproducitve Biology &Endocrinol,2010.8 ( 9 ) : 1311-1318.
  • 10M.Wong, S.O' Neilll, G.Walshl&I.E.Smithl. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes[J]. Annals of Oncology, 2013,24:133-138.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部